Testace vakcíny Biocan B inj. ad us. vet. a vývoj nové rekombinantní vakcíny proti borrelióze psů.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F25304046%3A_____%2F05%3A%230000001" target="_blank" >RIV/25304046:_____/05:#0000001 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis.

Popis výsledku v původním jazyce

Verification of efficacy of Biocan B inj. ad us. vet. was done by challenge test. Ticks were used as vectors of infection. Formation of OspA specific antibodies and borrelia specific immunoglobulins was measured in canine sera. Tissues were used for detection of borreliae by cultivation method and DFM. Formation of IgG and OspA antibodies after vaccination was observed. Results are presented in the article. Development of new vaccine is based on preparation of recombinant outer surface proteins of B. afzelii, B. burgdorferi and B. garinii origin. Recombinant proteins were expressed in E. coli. Obtained proteins are being tested. Formation of specific antibodies against some recombinant proteins was confirmed. These proteins are suitable candidates forpreparation of vaccine prototype and will be used in challenge tests.

Název v anglickém jazyce

Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis.

Popis výsledku anglicky

Verification of efficacy of Biocan B inj. ad us. vet. was done by challenge test. Ticks were used as vectors of infection. Formation of OspA specific antibodies and borrelia specific immunoglobulins was measured in canine sera. Tissues were used for detection of borreliae by cultivation method and DFM. Formation of IgG and OspA antibodies after vaccination was observed. Results are presented in the article. Development of new vaccine is based on preparation of recombinant outer surface proteins of B. afzelii, B. burgdorferi and B. garinii origin. Recombinant proteins were expressed in E. coli. Obtained proteins are being tested. Formation of specific antibodies against some recombinant proteins was confirmed. These proteins are suitable candidates forpreparation of vaccine prototype and will be used in challenge tests.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EI - Biotechnologie a bionika

OECD FORD obor

—

Projekt

<a href="/cs/project/FD-K3%2F100" target="_blank" >FD-K3/100: *Biotechnologie výroby antigenů Borrelia burgdorferi sensu lato pro přípravu prototypu vakcíny proti Lymeské borelióze.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2005

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

149

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

297-302

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—